Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors
This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors
Solid Tumor
DRUG: AM003
Number of SAEs, TEAEs assessed by CTCAE v.5.0, First 28 days of treatment|Number of TEAEs meeting protocol defined DLT criteria, Number and percent of participants experiencing dose-limiting toxicities (DLTs), Grade 3 non-hematological adverse AEs, Grade 4 hematological AEs, and discontinuations of study drug due to AE intolerance., First 28 days of treatment
Number of participants responding to treatment by RESICT 1.1 criteria, Estimating the ORR, Disease Control Rate, CR, PR and SD lasting at least 8 weeks by RECIST 1.1, Duration of the study, estimated to be 6 months|Number of participants responding to treatment by iRECIST criteria, Estimating the ORR, Disease Control Rate, CR, PR and SD lasting at least 8 weeks by iRECIST., Duration of the study, estimated to be 6 months|AM003 PK parameters - Cmax, Maximum concentration (Cmax), First 5 weeks of treatment|AM003 PK parameters - AUC, Area under the curve (AUC)., First 5 weeks of treatment
This is a phase 1, open-label , multicenter dose escalation trial evaluating the safety and tolerability of AM003 , administered intratumorally to patients with locally advanced and metastatic solid tumors